View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 20, 2022

Australian TGA grants approval to two oral medicines for Covid-19

The medications are the first oral treatments for Covid-19 to be approved in the country.

The Australian Therapeutic Goods Administration (TGA) has provisionally approved the use of two oral Covid-19 treatments, Merck Sharp & Dohme’s Lagevrio (molnupiravir) and Pfizer’s Paxlovid (nirmatrelvir and ritonavir).

Both products are indicated for use in adult patients at an increased risk of disease progression to hospitalisation or death and who do not require oxygen.

TGA noted that the oral medications need to be given as soon as possible after diagnosing the disease within five days of symptoms onset and cannot be used as a substitute for Covid-19 vaccines.

They are also claimed to be the first oral treatments for Covid-19 to be approved in the country.

Molnupiravir, which is available in the form of capsules, works by inhibiting the SARS-CoV-2 virus replication.

Paxlovid comprises two separate tablets of nirmatrelvir and ritonavir.

Nirmatrelvir blocks the protease enzyme activity and is taken in combination with a low ritonavir dose for maintaining nirmatrelvir’s plasma levels during the treatment.

TGA stated that both molnupiravir and Paxlovid are administered twice a day for five days.

TGA said in a statement: “The use of Lagevrio is not recommended in pregnancy and breastfeeding.

“The use of Paxlovid is also not recommended in pregnancy or breastfeeding, and in women of childbearing potential.”

Both the treatments have already received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) and conditional marketing authorisation from the UK Medicines and Healthcare Products Regulatory Agency.

Earlier this week, Paxlovid received authorisation from Health Canada.

The Australian Government has secured access to 300,000 courses of molnupiravir and 500,000 Paxlovid courses. They will be supplied this year and the first deliveries are expected in coming weeks.

In March last year, TGA approved the use of Vertex’s Trikafta (elexacaftor, tezacaftor, ivacaftor and ivacaftor) to treat people with cystic fibrosis aged 12 years and older.

Related Companies

Free Report

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy